Evidence map›Paper›PMID 28432083›Full record

ArticleJournal of leukocyte biology2017

Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production.

Paurvi Shinde, Wenhai Liu, Antoine Ménoret, Andrew D Luster, Anthony T Vella

Open access · bronzeAbstract read
In one paragraph

Article in Journal of leukocyte biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. The Protective Role of IL-36/IL-36R Signal in Con A-Induced Acute Hepatitis.Journal of immunology (Baltimore, Md. : 1950) · 2022
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Paurvi ShindeDepartment of Immunology, School of Medicine, University of Connecticut Health, Farmington, Connecticut, USA.
Wenhai LiuDepartment of Immunology, School of Medicine, University of Connecticut Health, Farmington, Connecticut, USA.
Antoine MénoretDepartment of Immunology, School of Medicine, University of Connecticut Health, Farmington, Connecticut, USA.
Andrew D LusterCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Anthony T VellaDepartment of Immunology, School of Medicine, University of Connecticut Health, Farmington, Connecticut, USA; vella@uchc.edu.
UConn Health · USHarvard University · US

Funding

Sustained adaptive immunity in the mucosaP01AI056172 · NIAID · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI VELLA, ANTHONY T · 2003 to 2017
$22.3M
NIAID NIH HHS P01 AI056172
6 · The paper itself

Abstract

LPS is a powerful adjuvant, and although LPS-mediated TLR4 signaling has been exquisitely delineated, the in vivo mechanism of how TLR4 responses impact T cell priming is far less clear. Besides costimulation, TNF and type 1 IFN are dominant cytokines released after TLR4 activation and can shape T cell responses, but other downstream factors have not been examined extensively. Depending on context, we show that IFNαR1 blockade resulted in minor to major effects on specific CD4 T cell clonal expansion. To help explain these differences, it was hypothesized that IFNαR1 blockade would inhibit specific T cell migration by reducing chemokine receptor signaling, but specific CD4 T cells from IFNαR1-blocked mice were readily able to migrate in response to specific chemokines. Next, we examined downstream factors and found that type 1 IFN signaling was necessary for chemokine production, even when mice were immunized with specific Ag with LPS and CD134 costimulation. IFNαR1 signaling promoted CXCL9 and CXCL10 synthesis, suggesting that these chemokines might be involved in the LPS and CD134 costimulation response. After immunization, we show that CXCL9 blockade inhibited CD4 T cell accumulation in the liver but also in LNs, even in the presence of elevated serum IFN-β levels. Thus, whereas type 1 IFN might have direct effects on primed CD4 T cells, the downstream chemokines that play a role during migration also impact accumulation. In sum, CXCL9 production is a key benchmark for productive CD4 T cell vaccination strategies.

Indexed as

AnimalsCD4-Positive T-LymphocytesCell ProliferationChemokine CXCL10Chemokine CXCL9Interferon-betaLipopolysaccharidesMiceMice, KnockoutReceptor, Interferon alpha-betaReceptors, OX40Signal TransductionToll-Like Receptor 4Chemokine CXCL10Chemokine CXCL9Cxcl10 protein, mouseCxcl9 protein, mouseIfnar1 protein, mouseInterferon-betaLipopolysaccharidesReceptor, Interferon alpha-betaReceptors, OX40Tlr4 protein, mouseTnfrsf4 protein, mouseToll-Like Receptor 4T cell expansionTLR4Type I IFN

Identifiers

PMID28432083
PMCPMC5470836
OpenAlexW2607174691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.